Infections in patients with mantle cell lymphoma.

Advancements in treatments have significantly improved the prognosis for mantle cell lymphoma (MCL), and there is a growing population of survivors with an increased susceptibility to infections. We assessed the incidence of infections by clinical characteristics and treatment both before and after MCL diagnosis in Sweden. Patients with a diagnosis of MCL ≥ 18 years between 2007 and 2019 were included, along with up to 10 matched comparators. Infectious disease diagnosis and anti-infective drug dispensation were identified by the National Patient and the Prescribed Drug Registers, respectively. Patients and comparators were followed from the diagnosis/matching date until death, emigration, or June 30, 2020. Overall, 1559 patients and 15,571 comparators were followed for a median duration of 2.9 and 5 years, respectively. The infection rate among patients was twofold higher, RRadj = 2.14 (2.01-2.27), contrasted to the comparator group. There was a notable rise in infection rates already 4 years before MCL diagnosis, which reached a fourfold increase in the first year after diagnosis and persisted significantly increased for an additional 8 years. Among patients, 69% (

Informations de copyright

© 2024 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.

Déclaration de conflit d'intérêts

Mats Jerkeman received honoraria from Abbvie, AstraZeneca, BMS, Kite/Gilead, Pierre Fabre, Roche, Sobi, and Takeda and research support from Abbvie, AstraZeneca, BMS, and Roche. Ingrid Glimelius received research support from Takeda and participated in educational sessions arranged by Janssen Cilag, Abbvie, and Kite Gilead. Karin E. Smedby received honoraria from Incyte and Celgene, and research support from Janssen Cilag. The other authors have no relevant financial or nonfinancial interests to disclose.